Embecta Corp (EMBC) valuation
Embecta P/E ratio history
Embecta trades at 4.3 times its earnings over the last twelve months and 3.5 times the earnings analysts expect over the next twelve. At its last 4 fiscal year ends its P/E ranged from 7.4 (year to Sep 2022) to 12.3 (year to Sep 2023), with a median of 9.6.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Sep 30, 2025 | $14.11 | $1.62 | 8.7 | — |
| Sep 30, 2024 | $14.10 | $1.34 | 10.5 | 6.1 |
| Sep 30, 2023 | $15.05 | $1.22 | 12.3 | 7.2 |
| Sep 30, 2022 | $28.79 | $3.89 | 7.4 | 7.5 |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Embecta valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| EmbectaEMBC | $371M | 4.3 | 3.5 | 0.4 |
| Viemed HealthcareVMD | $371M | 26.9 | 20.2 | 1.2 |
| RegenxbioRGNX | $372M | — | — | 2.1 |
| Tectonic TherapeuticTECX | $373M | — | — | — |
| Capricor TherapeuticsCAPR | $369M | — | — | — |
| Orthofix MedicalOFIX | $367M | — | 23.3 | 0.4 |
| RezoluteRZLT | $380M | — | — | — |
| Strata Critical Medical Inc ClassSRTA | $384M | 8.9 | — | 1.5 |
| Fennec PharmaceuticalsFENC | $356M | — | 16.2 | 6.0 |
| Peer median | 17.9 | 20.2 | 1.5 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: EMBC financials · EMBC returns
No forecast, no recommendation. This page describes Embecta Corp from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.